inVentiv Health, a global provider of clinical development and comprehensive commercialization services, announced expansion of compliance products and services to assist biopharmaceutical companies conducting non-interventional studies globally.
inVentiv Health, a global provider of clinical development and comprehensive commercialization services, announced expansion of compliance products and services to assist biopharmaceutical companies conducting non-interventional studies (NIS) globally. The announcement is related to changes in the EU Directive governing clinical trials, which takes effect May 2016. inVentiv Health believes the regulation could cause confusion around the conducting of non-interventional trials (also known as observational studies) because of vague regulatory language and establishment of a new category of trial with its own compliance requirements.
The new series of proprietary inVentiv Health resources are now available to address this issue and include:
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.